Phase 3, Randomized, double-blind, placebo-controlled, 26 week multicenter study to evaluate the efficacy and safety of Ertugliflozin in Asian Subjects with Type 2 Diabetes Mellitus and inadequate glycemic control on metformin monotherapy - Trial PHRR160502-001211
Access comprehensive clinical trial information for PHRR160502-001211 through Pure Global AI's free database. This Phase 3 trial is sponsored by Merck Sharp & Dohme Corporation and is currently Ongoing. The study focuses on Type 2 Diabetes mellitus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
PHRR160502-001211
Phase 3
Ongoing
Trial Details
Philippine Health Research Registry • PHRR160502-001211
Phase 3, Randomized, double-blind, placebo-controlled, 26 week multicenter study to evaluate the efficacy and safety of Ertugliflozin in Asian Subjects with Type 2 Diabetes Mellitus and inadequate glycemic control on metformin monotherapy
Study Focus
Interventional
Sponsor & Location
Merck Sharp & Dohme Corporation
Timeline & Enrollment
Phase 3
Jun 20, 2016
May 23, 2017
ICD-10 Classifications
Type 2 diabetes mellitus
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications
Data Source
Philippine Health Research Registry
PHRR160502-001211
Non-Device Trial